Biotech firm Immunis has published an article on the potential of secretomes for age and disease-related immune decline. Titled “The (Secret)ome to Longevity”, the piece explores how secretomes, the total set of substances secreted by a cell, can aid in disease prevention and immune system health. Immunis is developing a novel secretome therapeutic and is currently conducting a Phase 1/2a clinical trial for treating age-related muscle atrophy. The secretome from stem cell derivatives offers therapeutic benefits over traditional stem cell-based therapies and presents a potential new treatment option in biomedicine.
Business Wire reported

Immunis Inc. Sheds Light on the Potential of Secretomes in Age and Disease-Related Immune Decline

IRVINE, Calif., July 26, 2023

— Immunis Inc., a leading private biotech firm, is pioneering a novel secretome-based therapy to tackle immune decline associated with aging and disease. The company recently published an insightful article titled “The (Secret)ome to Longevity,” authored by Immunis’ Senior Scientific Communications Manager, Karissa Munoz, Ph.D.

Understanding the Role of the Immune System

The human immune system is crucial to our health. It consists of a complex network of cells, tissues, and secretions that protect the body from illnesses and infections. The immune system is divided into two main branches: the innate and adaptive immune responses. The balance between inflammatory and anti-inflammatory responses, often termed “immunomodulation,” is vital for these systems to function effectively.

Impact of Aging on the Immune System

As we age, our immune system also ages, leading to less effective functioning. This can result in an imbalance in the inflammatory and anti-inflammatory responses, leading to chronic low-level inflammation that is not conducive to repair or regeneration. This immune dysfunction is often the root cause of many age-related diseases.

The Promise of the Secretome

The secretome is a collection of substances secreted by a cell, including proteins, lipids, growth factors, chemokines, cytokines, exosomes, and microvesicles. It plays a crucial role in resolving infections and alleviating cellular damage. However, identifying specific secretome factors that combat disease remains a challenge.

Secretome-Based Therapies: A New Frontier

As we age, we lose the ability to produce new stem cells and the benefits of their secretome. Secretome-based therapies are being explored as an alternative to stem cell therapies, as they contain components that may be involved in the maintenance, differentiation, and regeneration of resident stem cells. Secretome-based therapies offer several advantages over stem cell treatments, including reduced risk of immune system rejection and tumorigenicity, ease of manufacturing, scalability for mass production, cost-effectiveness, and versatile treatment applications.

Immunis Inc.’s Contribution to Secretome Research

Immunis Inc. is at the forefront of research into secretome therapy. The company’s investigational secretome product has demonstrated immunomodulatory and regenerative capabilities in preclinical trials. Immunis is currently conducting an FDA-approved Phase 1/2a clinical trial in aged patients with osteoarthritis-related muscle deterioration to research the safety and tolerability of the investigational treatment.

About Immunis Inc.

Immunis is a private biotech company developing an innovative immunomodulatory secretome product to address age and disease-related immune decline. The company is leveraging its leading-edge capabilities in secretome technology to deliver a product containing all natural, all human immune modulators in their natural relative physiological concentrations.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, and these statements are only predictions. Forward-looking statements speak only as of the date they are made, and Immunis does not intend to update or revise any forward-looking statements.

Contacts

Please reach out to contact@immunisbiomedical.com for more information..